Cargando…
Clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy
AIMS: This study aimed to identify factors for attention leading to future pacing device implantation (PDI) and reveal the necessity of prophylactic PDI or implantable cardioverter-defibrillator (ICD) implantation in transthyretin amyloid cardiomyopathy (ATTR-CM) patients. METHODS AND RESULTS: This...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228612/ https://www.ncbi.nlm.nih.gov/pubmed/37099643 http://dx.doi.org/10.1093/europace/euad105 |
_version_ | 1785051002042318848 |
---|---|
author | Kawahara, Yusei Kanazawa, Hisanori Takashio, Seiji Tsuruta, Yuichiro Sumi, Hitoshi Kiyama, Takuya Kaneko, Shozo Ito, Miwa Hoshiyama, Tadashi Hirakawa, Kyoko Ishii, Masanobu Tabata, Noriaki Yamanaga, Kenshi Fujisue, Koichiro Hanatani, Shinsuke Sueta, Daisuke Arima, Yuichiro Araki, Satoshi Usuku, Hiroki Nakamura, Taishi Yamamoto, Eiichiro Soejima, Hirofumi Matsushita, Kenichi Kawano, Hiroaki Tsujita, Kenichi |
author_facet | Kawahara, Yusei Kanazawa, Hisanori Takashio, Seiji Tsuruta, Yuichiro Sumi, Hitoshi Kiyama, Takuya Kaneko, Shozo Ito, Miwa Hoshiyama, Tadashi Hirakawa, Kyoko Ishii, Masanobu Tabata, Noriaki Yamanaga, Kenshi Fujisue, Koichiro Hanatani, Shinsuke Sueta, Daisuke Arima, Yuichiro Araki, Satoshi Usuku, Hiroki Nakamura, Taishi Yamamoto, Eiichiro Soejima, Hirofumi Matsushita, Kenichi Kawano, Hiroaki Tsujita, Kenichi |
author_sort | Kawahara, Yusei |
collection | PubMed |
description | AIMS: This study aimed to identify factors for attention leading to future pacing device implantation (PDI) and reveal the necessity of prophylactic PDI or implantable cardioverter-defibrillator (ICD) implantation in transthyretin amyloid cardiomyopathy (ATTR-CM) patients. METHODS AND RESULTS: This retrospective single-center observational study included consecutive 114 wild-type ATTR-CM (ATTRwt-CM) and 50 hereditary ATTR-CM (ATTRv-CM) patients, neither implanted with a pacing device nor fulfilling indications for PDI at diagnosis. As a study outcome, patient backgrounds were compared with and without future PDI, and the incidence of PDI in each conduction disturbance was examined. Furthermore, appropriate ICD therapies were investigated in all 19 patients with ICD implantation. PR-interval ≥220 msec, interventricular septum (IVS) thickness ≥16.9 mm, and bifascicular block were significantly associated with future PDI in ATTRwt-CM patients, and brain natriuretic peptide ≥35.7 pg/mL, IVS thickness ≥11.3 mm, and bifascicular block in ATTRv-CM patients. The incidence of subsequent PDI in patients with bifascicular block at diagnosis was significantly higher than that of normal atrioventricular (AV) conduction in both ATTRwt-CM [hazard ratio (HR): 13.70, P = 0.019] and ATTRv-CM (HR: 12.94, P = 0.002), whereas that of patients with first-degree AV block was neither (ATTRwt-CM: HR: 2.14, P = 0.511, ATTRv-CM: HR: 1.57, P = 0.701). Regarding ICD, only 2 of 16 ATTRwt-CM and 1 of 3 ATTRv-CM patients received appropriate anti-tachycardia pacing or shock therapy, under the number of intervals to detect for ventricular tachycardia of 16–32. CONCLUSIONS: According to our retrospective single-center observational study, prophylactic PDI did not require first-degree AV block in both ATTRwt-CM and ATTRv-CM patients, and prophylactic ICD implantation was also controversial in both ATTR-CM. Larger prospective, multi-center studies are necessary to confirm these results. |
format | Online Article Text |
id | pubmed-10228612 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-102286122023-05-31 Clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy Kawahara, Yusei Kanazawa, Hisanori Takashio, Seiji Tsuruta, Yuichiro Sumi, Hitoshi Kiyama, Takuya Kaneko, Shozo Ito, Miwa Hoshiyama, Tadashi Hirakawa, Kyoko Ishii, Masanobu Tabata, Noriaki Yamanaga, Kenshi Fujisue, Koichiro Hanatani, Shinsuke Sueta, Daisuke Arima, Yuichiro Araki, Satoshi Usuku, Hiroki Nakamura, Taishi Yamamoto, Eiichiro Soejima, Hirofumi Matsushita, Kenichi Kawano, Hiroaki Tsujita, Kenichi Europace Clinical Research AIMS: This study aimed to identify factors for attention leading to future pacing device implantation (PDI) and reveal the necessity of prophylactic PDI or implantable cardioverter-defibrillator (ICD) implantation in transthyretin amyloid cardiomyopathy (ATTR-CM) patients. METHODS AND RESULTS: This retrospective single-center observational study included consecutive 114 wild-type ATTR-CM (ATTRwt-CM) and 50 hereditary ATTR-CM (ATTRv-CM) patients, neither implanted with a pacing device nor fulfilling indications for PDI at diagnosis. As a study outcome, patient backgrounds were compared with and without future PDI, and the incidence of PDI in each conduction disturbance was examined. Furthermore, appropriate ICD therapies were investigated in all 19 patients with ICD implantation. PR-interval ≥220 msec, interventricular septum (IVS) thickness ≥16.9 mm, and bifascicular block were significantly associated with future PDI in ATTRwt-CM patients, and brain natriuretic peptide ≥35.7 pg/mL, IVS thickness ≥11.3 mm, and bifascicular block in ATTRv-CM patients. The incidence of subsequent PDI in patients with bifascicular block at diagnosis was significantly higher than that of normal atrioventricular (AV) conduction in both ATTRwt-CM [hazard ratio (HR): 13.70, P = 0.019] and ATTRv-CM (HR: 12.94, P = 0.002), whereas that of patients with first-degree AV block was neither (ATTRwt-CM: HR: 2.14, P = 0.511, ATTRv-CM: HR: 1.57, P = 0.701). Regarding ICD, only 2 of 16 ATTRwt-CM and 1 of 3 ATTRv-CM patients received appropriate anti-tachycardia pacing or shock therapy, under the number of intervals to detect for ventricular tachycardia of 16–32. CONCLUSIONS: According to our retrospective single-center observational study, prophylactic PDI did not require first-degree AV block in both ATTRwt-CM and ATTRv-CM patients, and prophylactic ICD implantation was also controversial in both ATTR-CM. Larger prospective, multi-center studies are necessary to confirm these results. Oxford University Press 2023-04-26 /pmc/articles/PMC10228612/ /pubmed/37099643 http://dx.doi.org/10.1093/europace/euad105 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Clinical Research Kawahara, Yusei Kanazawa, Hisanori Takashio, Seiji Tsuruta, Yuichiro Sumi, Hitoshi Kiyama, Takuya Kaneko, Shozo Ito, Miwa Hoshiyama, Tadashi Hirakawa, Kyoko Ishii, Masanobu Tabata, Noriaki Yamanaga, Kenshi Fujisue, Koichiro Hanatani, Shinsuke Sueta, Daisuke Arima, Yuichiro Araki, Satoshi Usuku, Hiroki Nakamura, Taishi Yamamoto, Eiichiro Soejima, Hirofumi Matsushita, Kenichi Kawano, Hiroaki Tsujita, Kenichi Clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy |
title | Clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy |
title_full | Clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy |
title_fullStr | Clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy |
title_full_unstemmed | Clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy |
title_short | Clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy |
title_sort | clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228612/ https://www.ncbi.nlm.nih.gov/pubmed/37099643 http://dx.doi.org/10.1093/europace/euad105 |
work_keys_str_mv | AT kawaharayusei clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy AT kanazawahisanori clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy AT takashioseiji clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy AT tsurutayuichiro clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy AT sumihitoshi clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy AT kiyamatakuya clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy AT kanekoshozo clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy AT itomiwa clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy AT hoshiyamatadashi clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy AT hirakawakyoko clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy AT ishiimasanobu clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy AT tabatanoriaki clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy AT yamanagakenshi clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy AT fujisuekoichiro clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy AT hanatanishinsuke clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy AT suetadaisuke clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy AT arimayuichiro clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy AT arakisatoshi clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy AT usukuhiroki clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy AT nakamurataishi clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy AT yamamotoeiichiro clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy AT soejimahirofumi clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy AT matsushitakenichi clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy AT kawanohiroaki clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy AT tsujitakenichi clinicalelectrocardiographicandechocardiographicparametersassociatedwiththedevelopmentofpacingandimplantablecardioverterdefibrillatorindicationinpatientswithtransthyretinamyloidcardiomyopathy |